CC
BMY.RT

Clearline Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Clearline Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,200
Closed -$37K – 100
2020
Q2 		$37K Buy
+10,200
New +$36.8K 0.01% 66

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Clearline Capital's BMY.RT Position: Q3 2020 in Review

Clearline Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 10,200 shares — an estimated $37K sold.

Clearline Capital first reported a position in BMY.RT in Q2 2020 and held it in 1 quarter. The position peaked at $37K in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Clearline Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Clearline Capital sold 10,200 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $37K.
  • Clearline Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 1 quarter.
  • Clearline Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $37K in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Clearline Capital's 13F filing for Q3 2020, filed 16 Nov 2020.